Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691822 | 1.00 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KDM1A | |
| SCHEMBL3839739 | 0.89 | PTPN1 (0.41) | KDM1APTPN1GSK3BMTNR1AMTNR1B | |
| SCHEMBL3839743 | 0.89 | PTPN1 (0.41) | KDM1APTPN1GSK3BMTNR1AMTNR1B | |
| SCHEMBL10457458 | 0.83 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2MTNR1A | |
| SCHEMBL4693652 | 0.77 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4693559 | 0.75 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL10991192 | 0.73 | TBXAS1 (0.40) | KDM1APTPN1GSK3BMTNR1AMTNR1B | |
| SCHEMBL10991197 | 0.73 | TBXAS1 (0.40) | KDM1APTPN1GSK3BMTNR1AMTNR1B | |
| SCHEMBL30705332 | 0.72 | KDM1A (0.44) | KDM1AMTNR1AMTNR1BCYP1A2CYP2D6 | |
| Bromoethane SCHEMBL43961 | 0.71 | TDP1 (0.67) | CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603874-B1 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | PTGIS, PTGIR, PTGES | CYP3A4 481/4885TDP1 3710/4885ESR1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.